Sign In

7.11 : Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.

A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote glycine release, increasing chloride influx into postsynaptic neurons and reducing excitability.

GABA mimetics, such as baclofen, activate GABAB receptors, leading to hyperpolarization of neuronal membranes and reduced excitability. Baclofen suppresses the release of excitatory transmitters in the brain and spinal cord, suppressing sensory afferents, interneurons, and motor neurons.

Benzodiazepines like diazepam bind to the allosteric site of GABAA receptors and facilitate GABA's action in the CNS. Diazepam reduces spasticity, particularly in the spinal cord, but sedation can occur at doses required to reduce muscle tone.

Tags
Spasmolytic AgentsMuscle SpasmsSpasticityChemical ClassificationCentrally Acting Spasmolytics2 agonistTizanidine2 adrenoceptorsGlutamateGlycineChloride InfluxGABA MimeticsBaclofenGABAB ReceptorsHyperpolarizationBenzodiazepinesDiazepamGABAA ReceptorsCNS Sedation

From Chapter 7:

article

Now Playing

7.11 : Spasmolytic Agents: Chemical Classification

Skeletal Muscle Relaxants

765 Views

article

7.1 : Neuromuscular Junction And Blockade

Skeletal Muscle Relaxants

1.9K Views

article

7.2 : Classification of Skeletal Muscle Relaxants

Skeletal Muscle Relaxants

2.1K Views

article

7.3 : Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Skeletal Muscle Relaxants

972 Views

article

7.4 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Skeletal Muscle Relaxants

276 Views

article

7.5 : Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

Skeletal Muscle Relaxants

356 Views

article

7.6 : Depolarizing Blockers: Mechanism of Action

Skeletal Muscle Relaxants

839 Views

article

7.7 : Depolarizing Blockers: Pharmocokinetics

Skeletal Muscle Relaxants

228 Views

article

7.8 : Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Skeletal Muscle Relaxants

433 Views

article

7.9 : Skeletal Muscle Relaxants: Adverse Effects

Skeletal Muscle Relaxants

251 Views

article

7.10 : Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants

380 Views

article

7.12 : Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal Muscle Relaxants

2.7K Views

article

7.13 : Centrally Acting Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants

395 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved